Results 171 to 180 of about 19,505 (219)
Some of the next articles are maybe not open access.
Exacerbation of Psoriasis by the Hypolipidemic Agent, Gemfibrozil
Archives of Dermatology, 1988To the Editor.— Elicitation or exacerbation of psoriasis has occurred following administration of the psychopharmacologic agents, 1 β-blockers, 2 nonsteroidal anti-inflammatory agents, 3 antimalarials, 4 isotretinoin, 5 and chlorthalidone. 6 Abel and coworkers 7 have extensively analyzed and discussed the entire subject of drug-induced psoriasis in an
D A, Fisher, P M, Elias, P L, LeBoit
openaire +3 more sources
Metabolic Effects of a New Hypolipidemic Agent, Ciprofibrate
Journal of Pharmaceutical Sciences, 1979Ciprofibrate, a new orally effective hypolipidemic agent like clofibrate, suppressed tyloxapol-induced hypercholesterolemia in rats. Ciprofibrate at 10 mg/kg was effective. Clofibrate required a dosage of 180 mg/kg to suppress the tyloxapol effect. Norepinephrine-induced free fatty acid release was inhibited by clofibrate in rats in accordance with ...
A, Arnold, M P, McAuliff, A L, Beyler
openaire +2 more sources
Lentysine: A new hypolipidemic agent from a mushroom
Life Sciences, 1970Abstract The actions of lentysine on the serum and liver lipids in rats have been investigated. Lentysine markedly reduced serum cholesterol, phospholipids and triglycerides, both in intact rats and in animals fed a high fat diet. However, this substance showed no effect on liver lipid levels.
T, Rokujo +6 more
openaire +2 more sources
Investigation of 3,5-Isoxazolidinediones as Hypolipidemic Agents in Rodents
Pharmaceutical Research, 1995A series of 2-benzoyl-4,4-dialkyl-3,5-isoxazolidinediones proved to have potent hypolipidemic activity, lowering both serum cholesterol and triglyceride levels at 10 or 20 mg/kg/day, IP and orally in rodents. 2-(3,4,5-Trimethoxybenzoyl)-4,4-diethyl-3,5-isoxazolidinedione+ ++ (4) afforded the best hypolipidemic activity lowering normolipidemic CF1 mouse
T, Woodard +7 more
openaire +2 more sources
Hypolipidemic agents in the secondary prevention of the stroke
Galenika Medical Journal, 2022Stroke is one of the leading causes of morbidity, mortality and disability in the world, and fat metabolism disorder is one of the most significant risk factors for its occurrence. Numerous studies have confirmed that lowering LDL cholesterol with the use of statins significantly reduces the risk of ischemic stroke (AIS).
openaire +1 more source
[Aryloxy- and arylthioalkylamine hypolipidemic agents].
Il Farmaco; edizione scientifica, 1983Aryloxy and arylthioalkylamines related respectively to clofibrate and 2-(3,5-di-t-butyl-4-hydroxyphenylthio)hexanoic acid, a derivative of an active probucol metabolite, were prepared and pharmacologically screened as hypolipidemic substances. Some of them showed interesting antilipemic activity but also, unfortunately, high acute toxicity.
DURANTI E +5 more
openaire +2 more sources
[Peroxisomes and hypolipidemic agents ].
La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1982Peroxisomes (microbodies) have been localized in the cytoplasm of various cells, mainly the hepatocytes and the renal tubular cells. Various enzymes were found in the granular matrix and sometimes in the nucleus; they were involved in the production and the degradation of hydrogen peroxide, in regulation of the energetic processes of the cell, and in ...
F, Heller, S, Pourbaix
openaire +1 more source
[Pharmacology of hypolipidemic agents].
Revue medicale de Bruxelles, 1997This review article examines the mode of action, the efficacy and the side effects of the various types of hypolipidemic agents (fibrates, bile acid sequestrants, statins, nicotinic acid and acipimox) currently available in Belgium. It also summarizes the recent guidelines recommended by the Belgian Lipid Club in the management of hyperlipidemia for ...
F, Féry, E O, Balasse
openaire +1 more source
FDA considerations regarding new hypolipidemic agents
Lipids, 1977AbstractFood and Drug Administration policy being considered for new marketed hypolipidemic agents includes: long‐term safety to be demonstrated in postmarketing studies; evidence of clinical effectiveness to be demonstrated within a specified time period. Effectiveness is to be judged by one or more of the following: reduction in xanthomata, reduction
openaire +2 more sources
Comparative study of several hypolipidemic agents related to clofibrate
Atherosclerosis, 1974Abstract Clofibrate and 3 related drugs (13.437 SU, GP 45.699 and MK 185) have been tested in man with the same protocol and by the same medical team. Comparison of the results of these clinical trials shows that the 4 drugs have common effects with regard to lipidemia, but differ in their action on uricemia and tolerance to antivitamin K: All of ...
V, Beaumont +3 more
openaire +2 more sources